Ardelyx's 2025 net loss widens

Reuters

Feb 20

<a href="https://laohu8.com/S/ARDX">Ardelyx</a>'s 2025 net loss widens

Overview

Biopharmaceutical firm's Q4 product sales reached $114.4 mln
Company's 2025 revenue reaches $407.3 mln
Net loss for 2025 widened to $61.6 mln from $39.1 mln in 2024

Outlook

Ardelyx expects 2026 IBSRELA revenue to be between $410 and $430 mln
Company anticipates 2026 XPHOZAH revenue between $110 and $120 mln

Result Drivers

IBSRELA GROWTH - Revenue for IBSRELA grew 73% in 2025 to $274.2 mln, driven by increased prescribing and patient engagement
XPHOZAH DISPENSES - XPHOZAH revenue reached $103.6 mln in 2025, reflecting growth in total dispenses, including non-Medicare patients

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Product Sales		$114.40 mln
Q4 Net Income		-$407,000
Q4 Operating Income		$5.10 mln

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Ardelyx Inc is $14.00, about 108.3% above its February 18 closing price of $6.72
The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 92 three months ago

Press Release: ID:nGNX11lgdZ

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612238011"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612238011\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612238011?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612238011","market":"nz","top_or_hot":-1,"title":"Ardelyx's 2025 net loss widens","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>'s 2025 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 product sales reached $114.4 mln</p></li><li><p>Company's 2025 revenue reaches $407.3 mln</p></li><li><p>Net loss for 2025 widened to $61.6 mln from $39.1 mln in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ardelyx expects 2026 IBSRELA revenue to be between $410 and $430 mln</p></li><li><p>Company anticipates 2026 XPHOZAH revenue between $110 and $120 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>IBSRELA GROWTH - Revenue for IBSRELA grew 73% in 2025 to $274.2 mln, driven by increased prescribing and patient engagement</p></li><li><p>XPHOZAH DISPENSES - XPHOZAH revenue reached $103.6 mln in 2025, reflecting growth in total dispenses, including non-Medicare patients</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Sales</p></td><td></td><td><p>$114.40 mln</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$407,000</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>$5.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Ardelyx Inc is $14.00, about 108.3% above its February 18 closing price of $6.72</p></li><li><p>The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 92 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX11lgdZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ardelyx's 2025 net loss widens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArdelyx's 2025 net loss widens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 05:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ARDX\">Ardelyx</a>'s 2025 net loss widens</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 product sales reached $114.4 mln</p></li><li><p>Company's 2025 revenue reaches $407.3 mln</p></li><li><p>Net loss for 2025 widened to $61.6 mln from $39.1 mln in 2024</p></li></ul><p><span>Outlook</span></p><ul><li><p>Ardelyx expects 2026 IBSRELA revenue to be between $410 and $430 mln</p></li><li><p>Company anticipates 2026 XPHOZAH revenue between $110 and $120 mln</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>IBSRELA GROWTH - Revenue for IBSRELA grew 73% in 2025 to $274.2 mln, driven by increased prescribing and patient engagement</p></li><li><p>XPHOZAH DISPENSES - XPHOZAH revenue reached $103.6 mln in 2025, reflecting growth in total dispenses, including non-Medicare patients</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Product Sales</p></td><td></td><td><p>$114.40 mln</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$407,000</p></td><td></td></tr><tr><td><p>Q4 Operating Income</p></td><td></td><td><p>$5.10 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy.\"</p></li><li><p>Wall Street's median 12-month price target for Ardelyx Inc is $14.00, about 108.3% above its February 18 closing price of $6.72</p></li><li><p>The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 92 three months ago</p></li></ul><p>Press Release: <span>ID:nGNX11lgdZ</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nL1N3ZF1AB:1","article_id":"2612238011","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612238011","pubTimestamp":1771535474,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ardelyx's 2025 net loss widensOverviewBiopharmaceutical firm's Q4 product sales reached $114.4 mlnCompany's 2025 revenue reaches $407.3 mlnNet loss for 2025 widened to $61.6 mln from $39.1 mln in 2024","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARDX":"Ardelyx"},"translate_title":"Ardelyx 2025年净亏损扩大","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARDX":0.9},"content_text":"Ardelyx's 2025 net loss widensOverviewBiopharmaceutical firm's Q4 product sales reached $114.4 mlnCompany's 2025 revenue reaches $407.3 mlnNet loss for 2025 widened to $61.6 mln from $39.1 mln in 2024OutlookArdelyx expects 2026 IBSRELA revenue to be between $410 and $430 mlnCompany anticipates 2026 XPHOZAH revenue between $110 and $120 mlnResult DriversIBSRELA GROWTH - Revenue for IBSRELA grew 73% in 2025 to $274.2 mln, driven by increased prescribing and patient engagementXPHOZAH DISPENSES - XPHOZAH revenue reached $103.6 mln in 2025, reflecting growth in total dispenses, including non-Medicare patientsKey DetailsMetricBeat/MissActualConsensus EstimateQ4 Product Sales$114.40 mlnQ4 Net Income-$407,000Q4 Operating Income$5.10 mlnAnalyst CoverageThe current average analyst rating on the shares is \"strong buy\" and the breakdown of recommendations is 12 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy.\"Wall Street's median 12-month price target for Ardelyx Inc is $14.00, about 108.3% above its February 18 closing price of $6.72The stock recently traded at 42 times the next 12-month earnings vs. a P/E of 92 three months agoPress Release: ID:nGNX11lgdZFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}